Loading...
Loading...
PEAR| Name | Value |
|---|---|
| Revenues | 3.3M |
| Cost of Revenue | 2.4M |
| Gross Profit | 0.9M |
| Operating Expense | 33.7M |
| Operating I/L | -32.8M |
| Other Income/Expense | 38.3M |
| Interest Income | 0.0M |
| Pretax | 5.5M |
| Income Tax Expense | -38.3M |
| Net Income/Loss | 43.7M |
Pear Therapeutics, Inc. is a commercial-stage healthcare company specializing in software-based medicines. The company's revenue is generated through the sale of its commercial products, including reSET for substance use disorder related to alcohol, cannabis, cocaine, and stimulants, reSET-O for opioid use disorder in combination with buprenorphine, and Somryst for chronic insomnia. Additionally, Pear Therapeutics is developing a pipeline of 14 product candidates focusing on psychiatry, neurology, and therapeutic areas such as gastrointestinal, oncology, and cardiovascular, expanding its potential revenue streams.
